Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,034 across all filing types
Latest filing 2023-09-27 Capital/Financing Update
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the signing of distribution and license agreements between Cosmo Pharmaceuticals and Glenmark Pharmaceuticals for the product Winlevi® in Europe and South Africa. It includes details about the agreement terms, market potential, and company backgrounds. There are no financial statements, regulatory filings, or detailed financial performance data. The document is clearly a media release announcing a business agreement, not a financial report, earnings release, or regulatory filing. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including licensing and distribution agreements that impact company operations and revenue streams.
2023-09-27 English
Credit Rating
Regulatory Filings Classification · 95% confidence The document is a formal communication from Glenmark Pharmaceuticals Limited to stock exchanges regarding the withdrawal of a voluntary issuer rating disclosure by India Ratings due to regulatory requirements. It includes a detailed explanation of the rating withdrawal, references to SEBI regulations, and a disclaimer from the rating agency. The document does not contain financial statements, management discussion, or detailed financial results. It is an official regulatory announcement informing the market about a change in rating disclosure practices. The length is about 5978 characters, which is relatively short and focused on a regulatory update rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-09-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) informing them about the schedule of upcoming analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides details of the meeting date, location, and type. The document is short (1680 characters) and does not contain any financial data, results, or detailed reports. It is an announcement of scheduled investor meetings rather than a report or presentation itself. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-09-22 English
News Verification
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India regarding a clarification/confirmation on a news item. It references disclosures made pursuant to SEBI Listing Obligations Regulation 30, specifically about the outcome of a board meeting, a press release, and an investor presentation related to a proposed divestment. The letter is short (1811 characters) and primarily serves to confirm and clarify information already disclosed. It does not contain financial statements, detailed financial data, or the full content of the reports mentioned. It is an official regulatory communication confirming prior disclosures rather than the disclosures themselves. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and confirmations that do not fit other specific categories.
2023-09-22 English
Investor Presentation
Capital/Financing Update Classification · 95% confidence The document is a press release and investor presentation announcing Glenmark Pharmaceuticals' proposed divestment of a majority stake in its subsidiary Glenmark Life Sciences. It includes transaction details, strategic rationale, and future roadmap but does not contain detailed financial statements or comprehensive financial analysis typical of an interim or annual report. The document is not a full financial report but rather an update on a capital transaction and strategic business decision. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing but a substantive update on financing activity.
2023-09-21 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release and investor presentation announcing Glenmark Pharmaceuticals' proposed divestment of a majority stake in its subsidiary Glenmark Life Sciences. It includes transaction details, strategic rationale, and future roadmap but does not contain detailed financial statements or comprehensive financial performance data. The document is not a full annual or interim report, nor is it an earnings release or regulatory filing. It is primarily an update on a capital transaction and strategic business decision, supported by an investor presentation. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (over 12,000 characters) and content confirm it is not a brief announcement or mere report publication notice.
2023-09-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.